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ABSTRACT 1 
Background  2 
In Mediterranean countries, adherence to a traditional Mediterranean dietary pattern (MedDiet) 3 
is associated with better cognitive function and reduced dementia risk.  It is unclear if similar 4 
benefits exist in non-Mediterranean regions.  5 
 6 
Objective 7 
To examine associations between MedDiet adherence and cognitive function in an older, UK 8 
population.  To investigate whether associations differed between individuals with high versus 9 
low cardiovascular disease (CVD) risk.    10 
 11 
Design 12 
We conducted an analysis in 8009 older individuals with dietary data at Health Check 1 (1993-13 
1997) and cognitive function data at Health Check 3 (2006-2011) of the European Prospective 14 
Investigation of Cancer, Norfolk (EPIC-Norfolk).  Associations were explored between 15 
MedDiet adherence and global and domain specific cognitive test scores and risk of poor 16 
cognitive performance in the entire cohort, and when stratified according to CVD risk status.  17 
 18 
Results  19 
Higher MedDiet adherence defined by the Pyramid MedDiet score was associated with better 20 
global cognition (β±SE=-0.012±0.002; P<0.001), verbal episodic memory (β±SE=-21 
0.009±0.002; P<0.001), and simple processing speed (β±SE=-0.002±0.001; P=0.013). Lower 22 
risk of poor verbal episodic memory (OR(95%CI)=0.784 (0.641,0.959); P=0.018), complex 23 
processing speed (OR(95%CI)=0.739 (0.601,0.907); P=0.004), and prospective memory 24 
(OR(95%CI)=0.841 (0.724,0.977); P=0.023) was also observed for the highest versus lowest 25 
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Pyramid MedDiet tertiles. The effect of a one-point increase in Pyramid score on global 26 
cognitive function was equivalent to 1.7 fewer years of cognitive ageing.  MedDiet adherence 27 
defined by the MEDAS score (mapped using both binary and continuous scoring) showed 28 
similar, albeit less consistent, associations. In stratified analyses, associations were evident in 29 
individuals at higher CVD risk only (P<0.05).   30 
 31 
Conclusions  32 
Higher adherence to the MedDiet is associated with better cognitive function and lower risk of 33 
poor cognition in older, UK adults.  This evidence underpins the development of interventions 34 
to enhance MedDiet adherence, particularly in individuals at higher CVD risk, aiming to 35 
reduce the risk of age-related cognitive decline in non-Mediterranean populations. 36 
 37 
 38 
KEYWORDS 39 
Mediterranean diet, cognitive function, cognitive decline, dementia risk, cardiovascular 40 
health, healthy ageing 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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INTRODUCTION 52 
The traditional Mediterranean diet (MedDiet) is characterised by a high intake of plant-based 53 
foods including fruits, vegetables, legumes, nuts and seeds, and whole grains.  Olive oil is used 54 
as the principal cooking fat, and added liberally to salads, bread, and pasta.  Additionally, fish 55 
and red wine are consumed in moderate amounts, whilst red meat, confectionery, and processed 56 
foods are consumed infrequently (1,2).  Higher adherence to a MedDiet has been associated 57 
with numerous beneficial health outcomes, particularly in older people, including lower risk of 58 
cardiovascular diseases (CVD) (3), type II diabetes (4), and some cancers (5,6).  Further, 59 
observational studies indicate a protective effect of the MedDiet against dementia, including 60 
Alzheimer’s disease (7,8), whilst results from the Navarra and Barcelona cohorts of the 61 
Prevención con Dieta Mediterránea (PREDIMED) randomised controlled trial (RCT) have 62 
demonstrated beneficial effects of a MedDiet intervention supplemented with additional nuts 63 
or extra virgin olive oil on cognitive function (9–11).   Outside the Mediterranean basin, few 64 
studies have explored associations between MedDiet adherence and cognitive function and 65 
dementia incidence (12). Existing evidence is mixed, with some studies reporting positive 66 
associations (13–15) and other studies reporting no significant associations between MedDiet 67 
adherence and cognitive function (16–18).  In the United Kingdom (UK) specifically, there is 68 
a paucity of research exploring associations between MedDiet adherence and cognitive 69 
function, with evidence limited to a cross-sectional study of participants from the 1936 Lothian 70 
Birth Cohort, which reported greater verbal ability with higher adherence to an a posteriori 71 
defined “Mediterranean-style” diet (19). A later analysis of this dataset also showed reduced 72 
brain atrophy with higher MedDiet adherence (20).  Large scale, prospective analyses 73 
exploring associations between MedDiet adherence and cognitive function with more 74 
comprehensive measures of exposure to the MedDiet are warranted.  75 
 76 
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Poor cardiovascular health is associated with higher risk of cognitive impairment and 77 
dementia (21–23), which has been related to systemic cardio-metabolic (e.g. cerebral hypo-78 
perfusion, dysfunctional glucose and lipid metabolism) and brain-specific (e.g. reduced β-79 
amyloid clearance, elevated inflammation and oxidative stress, reduced neurogenesis and 80 
neuronal survival, greater white matter hyper-intensities) mechanisms (24).  By protecting 81 
against one or more of these adverse effects, the MedDiet is likely to be particularly effective 82 
at reducing the risk of poor cognitive performance in individuals with higher CVD risk but 83 
this hypothesis has not been tested.   84 
  85 
In the present study, we used data from the Norfolk Cohort of the European Prospective 86 
Investigation of Cancer and Nutrition (EPIC-Norfolk) to investigate longitudinal associations 87 
between MedDiet adherence and cognitive function/risk of poor cognitive performance in an 88 
older UK population.  We tested whether associations between adherence to this dietary 89 
pattern and the risk of poor cognitive performance differed between individuals at lower and 90 
higher CVD risk.    91 
 92 
SUBJECTS AND METHODS 93 
Study population and design 94 
EPIC is an ongoing, multi-centre prospective cohort study, exploring the relationship between 95 
diet and disease across 10 European countries (25).  EPIC-Norfolk is one of two UK centres 96 
within EPIC. The design and methods of this study have been described comprehensively 97 
elsewhere (26).   Briefly, EPIC-Norfolk included a baseline health examination (Health Check 98 
1; HC1) of 25,639 men and women aged 40-79 years, recruited from East Anglia in England 99 
via general practice registers,  between 1993 and 1997.  Participants were invited to a follow 100 
up assessment (Health Check 2; HC2) between 1998 and 2000, which included those tests 101 
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undertaken at baseline plus further variables such as bone health.  Health Check 3 (HC3) was 102 
conducted between 2006 and 2011 in 8623 participants (aged 48–92 years at that time), to 103 
investigate conditions relevant to ageing, including cognitive function, loss of mobility, and 104 
loss of vision (27). Cognitive data were collected for 8585 individuals at HC3 (28).  105 
 106 
The present study evaluated associations between MedDiet adherence, quantified using food 107 
frequency questionnaire (FFQ) data obtained at HC1, and cognitive function, as determined 108 
via a comprehensive cognitive testing battery  at HC3. This analysis involved 8009 individuals 109 
who completed both dietary assessments at HC1 and cognitive measures at HC3 110 
(Supplementary Figure 1). The study was approved by the Norwich District Ethics 111 
Committee (HC1 & HC2: 98CN01; HC3: 05/Q0101/191) and East Norfolk and Waveney NHS 112 
Research Governance Committee (2005EC07L). Participants provided informed consent.    113 
 114 
Dietary assessment and calculation of Mediterranean diet scores 115 
A 130-item, semi-quantitative FFQ, extensively used and validated in previous research (29–116 
31), was used to evaluate the habitual diet of participants over the past year at HC1.  Food 117 
intake values were calculated from the FFQ data using validated computer programs (32,33), 118 
and foods were grouped into relevant categories which were used for the creation of the various 119 
MedDiet scores (e.g. total fruit intake or total vegetable intake).  Dietary data were energy-120 
adjusted (2000 kcal/d (8.4 MJ/d)) via the residuals method (34) to allow evaluation of diet 121 
quality independent of diet quantity (35).  Briefly, log transformed dietary variables were used 122 
to create residuals with more consistent variance across the levels of total energy intake.  Values 123 
were back-transformed by adding the residuals to a constant, equivalent to the predicted value 124 
for the log of 2000 kcal, and then calculating the antilog.  Three MedDiet scores were then 125 
calculated as measures of adherence to the MedDiet pattern.  These were: i) the MEDAS score 126 
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(categorical), ii) the MEDAS Continuous score, and iii) the MedDiet pyramid (Pyramid) score. 127 
The MEDAS score is a 14-point score used to track MedDiet adherence in the aforementioned 128 
PREDIMED RCT (3).  As recently validated for use in UK populations (36), the standard 129 
MEDAS score was calculated with participants allocated 0 or 1 points per food item depending 130 
on whether they achieved the cut off for the dietary target. The MEDAS Continuous score was 131 
developed as part of the current analysis to provide greater sensitivity. It was calculated using 132 
the same dietary targets as the standard MEDAS score but with points allocated on a continuous 133 
basis (i.e. between 0 and 1) depending on closeness to the dietary target.   The Pyramid score 134 
is a 15-point scoring system proposed by the Mediterranean Diet Foundation (1) that was used 135 
previously for the EPIC-Norfolk cohort by Tong et al. (35). It is also coded on a continuous 136 
basis. Details of the calculations used for each of the MedDiet scores are provided in 137 
Supplementary Tables 1 and 2. 138 
 139 
Assessment of cognitive function 140 
Tests were selected to cover a range of different cognitive domains (37).  The number of 141 
participants for whom both dietary data at HC1 and cognitive test data for each specific 142 
outcome at HC3 are available is as follows:  143 
1) Global cognitive function: Total score from a shortened version of the Extended 144 
Mental State Exam (SF-EMSE; n = 7917).  145 
2) Verbal episodic memory: Total score from the Hopkins Verbal Learning test (HVLT; 146 
n = 7589). 147 
3) Non-verbal episodic memory: The first trial memory score of the Paired Associates 148 
Learning Test from the Cambridge Neuropsychological Test Battery (CANTAB-PAL; 149 
n = 6970). 150 
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4) Attention: Accuracy score (number of targets correctly identified – number missed) 151 
from the Letter Cancellation Task, as applied in the Medical Research Council 152 
Cognitive Function and Ageing study (MRC-CFAS; n = 7847).  153 
5) Simple processing speed: Mean response time of the Simple Visual Sensitivity Test 154 
(VST; n = 6685). 155 
6) Complex processing speed and visual deficits contributing to cognitive 156 
impairment: Mean response time of the Complex VST (n = 6685). 157 
7) Memory: Pass or fail of the Prospective Memory Test, as also described in the MRC-158 
CFAS (n = 7841). 159 
 160 
Assessment of other covariates 161 
At each health check, a self-administered questionnaire was used to capture participant 162 
demographics, lifestyle, and health characteristics.  Physical activity over the past year was 163 
determined via a simple, validated questionnaire, and a four-level index which was validated 164 
against heart rate was derived (38). Trained nurses measured the weight, height, waist 165 
circumference and blood pressure (BP) of participants, and obtained blood samples.   166 
 167 
Statistical analyses 168 
All statistical analyses were conducted using SPSS version 24. Statistical significance was 169 
defined as P < 0.05.   170 
 171 
Cohort characteristics 172 
Cohort characteristics at HC1 were compared between low, medium and high MedDiet 173 
adherence groups for each MedDiet score using the Kruskal-Wallis test for ordered and non-174 
normally distributed continuous variables and the chi squared test for nominal variables.   175 
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Mediterranean diet adherence and cognitive function 176 
Linear regression was used to investigate associations between MedDiet adherence at HC1 and 177 
cognitive function at HC3, with adjustment for relevant covariates (see statistical models).  178 
Scores for the SF-EMSE and HVLT were negatively skewed, and therefore transformed 179 
variables were derived and used for subsequent analyses as NEWVARIABLE = log10 (K – X), 180 
where NEWVARIABLE is the new variable name, K is equal to the maximum test score + 1, 181 
and X is equal to the untransformed score. Lower transformed scores on these tests reflect 182 
better cognitive performance (i.e. greater original scores).  VST-Simple and VST-complex 183 
scores were log transformed (log10).  Lower scores on this test reflect faster processing speed. 184 
Untransformed variables were used for the CANTAB-PAL and Letter Cancellation Task, with 185 
higher scores reflecting better performance. Results are presented as β-coefficients and 186 
standard errors (SE). The prospective memory test was not included in the linear regression 187 
analyses because it is binary (scored as pass or fail).  188 
 189 
Mediterranean diet adherence and risk of poor cognitive performance in the whole cohort 190 
and when stratified by CVD risk status 191 
Using the same cognitive data, but now categorised into normal and poor performance, 192 
associations between MedDiet adherence and risk of poor cognitive performance were 193 
explored via logistic regression. Poor performance on any test was defined as a score below 194 
the 10th percentile of the population distribution for each of the cognitive tests (28). Because 195 
19% of the population failed the prospective memory task, this was used as the lower cut-point 196 
for this outcome.   197 
 198 
Given the well documented associations between poor cardiovascular health and cognitive 199 
impairment (21–23), we performed stratified analyses which tested the hypothesis that the 200 
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effects of MedDiet adherence on risk of poor cognitive performance differed by CVD risk 201 
group.  Lower and higher CVD risk was defined as below and above the median QRISK2 score 202 
(which is indicative CVD risk in the next 10 years (39)).  Results are presented as odds ratios 203 
(OR) with 95% confidence intervals.  204 
 205 
Statistical models 206 
A series of statistical models was used to investigate associations between MedDiet adherence 207 
and cognitive function or risk of poor cognitive performance.  Models were adjusted for a range 208 
of covariates measured at the same point as the dietary exposure.  Additional covariates were 209 
added to the model as we progressed from Model 1 to Model 4 (i.e., basic to maximal 210 
adjustment) as follows: Model 1 adjusted for age, sex, body mass index (BMI), waist 211 
circumference, marital status, and employment status; Model 2 adjusted additionally for self-212 
reported medical conditions (heart attack, stroke, arrhythmia, diabetes, depression, and other 213 
psychological illness), self-reported medication (BP lowering, lipid lowering, steroids, diabetes 214 
medication), HDL and LDL cholesterol, triglycerides, smoking status, physical activity status, 215 
systolic BP and diastolic BP; Model 3 adjusted additionally for education; and,  Model 4 216 
adjusted additionally for APOE genotype (presence or absence of the APOE4 allele).   217 
 218 
Missing data 219 
At HC1, covariate data were missing for ≤ 0.5 % of participants for socioeconomic, lifestyle, 220 
anthropometric and BP data, ≤ 1.1 % for self-reported medical conditions, ≤ 7.4 % for 221 
circulating cholesterol and triglyceride concentrations, and 11.0 % for APOE genotype.  The 222 
missing data were imputed simultaneously using the SPSS multiple imputations procedure. 223 
Estimates from 10 datasets were pooled under Rubin’s rules in all subsequent analyses, unless 224 
otherwise stated.  225 
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Sensitivity analyses 226 
Sensitivity analyses were conducted to test the robustness of associations between MedDiet 227 
adherence and cognitive function/poor cognitive performance using dietary data obtained at 228 
HC2 instead of HC1.  In addition, to assess whether any individual components of the MedDiet 229 
drove the beneficial effects observed, we repeated the primary analyses (i.e. maximally 230 
adjusted linear regression models) in which a significant effect on cognition was observed after 231 
removing each MedDiet component from the total score, sequentially.  We also conducted a 232 
sensitivity analysis in which participants with potentially implausible energy intakes (i.e. over- 233 
or under-reporters) according to the Goldberg cut offs (40) were excluded from the main 234 
analysis. As an alternative method of exploring whether associations between MedDiet 235 
adherence and risk of poor cognitive performance differed by CVD risk status, we also 236 
performed analyses where we included an interaction term (diet * CVD risk group) in 237 
maximally adjusted models.  Finally, we explored differences in cohort characteristics between 238 
participants with and without complete cognitive testing data, to identify potential issues with 239 
selection bias.  240 
 241 
RESULTS 242 
Cohort characteristics 243 
Baseline participant characteristics are in Table 1, with additional details also provided in 244 
Supplementary Table 3.  Participants with high adherence to the MedDiet were less likely to 245 
be smokers, and more likely to be female, unmarried, more physically active, and have a higher 246 
education status compared with individuals with low MedDiet adherence. In addition, 247 
individuals with a high MedDiet adherence were more likely to have lower BMI, waist 248 
circumference, systolic and diastolic BP, triglyceride concentrations, and QRISK2 score, and 249 
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higher HDL-cholesterol concentrations, compared with individuals with low MedDiet 250 
adherence (all P<0.05).   251 
 252 
**INSERT TABLE 1 HERE** 253 
 254 
Associations between MedDiet adherence and cognitive function 255 
Associations between MedDiet adherence and cognitive performance are shown in Table 2.  256 
In the maximally adjusted linear regression models (model 4), higher MedDiet adherence, as 257 
characterised by all three MedDiet scores, was associated with significantly better performance 258 
on the SF-EMSE (global cognition; MEDAS: β±SE = -0.004 ± 0.002, P = 0.018; MEDAS 259 
Continuous: β±SE = -0.005 ± 0.002, P = 0.008; Pyramid:  β±SE = -0.012 ± 0.002, P <0.001). 260 
Higher adherence to the MedDiet (assessed using the Pyramid score) was also associated with 261 
significantly better performance on the HVLT (verbal episodic memory; β±SE = -0.009 ± 262 
0.002, P < 0.001) and VST-Simple (simple processing speed; β±SE = -0.002 ± 0.001, P = 263 
0.013).  To put this into perspective, the effects of a one point increase in MedDiet score 264 
(maximum 14-15 points) on SF-EMSE performance, a measure of global cognition, was 265 
equivalent to 0.57, 0.71, and 1.7 fewer years of ageing for the MEDAS, MEDAS Continuous, 266 
and Pyramid scores, respectively (β value for age in maximally adjusted models was 0.007, P 267 
< 0.001).   268 
 269 
**INSERT TABLE 2 HERE** 270 
 271 
Associations between MedDiet adherence and risk of poor cognitive performance 272 
Associations between MedDiet adherence and risk of poor cognitive performance are presented 273 
in Figure 1 and Supplementary Table 4.  In maximally adjusted models (model 4), high 274 
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compared with low MedDiet adherence as defined by the MEDAS Continuous score was 275 
associated with reduced risk of poor cognitive performance on the SF-EMSE (global cognition; 276 
OR (95% CI) = 0.828 (0.696, 0.985), P = 0.033) and HVLT (verbal episodic memory; OR 277 
(95% CI) = 0.797 (0.653, 0.973), P = 0.026).  Higher MedDiet adherence defined by the 278 
Pyramid score was associated with a lower risk of poor performance in the HVLT (OR (95% 279 
CI) = 0.784 (0.641, 0.959), P = 0.018), VST-Complex (OR (95% CI) = 0.739 (0.601, 0.907), 280 
P = 0.004), and Prospective memory task (Prospective memory; OR (95% CI) = 0.841 (0.724, 281 
0.977), P = 0.023).  Moderate MedDiet adherence defined by the MEDAS Continuous score 282 
and the Pyramid score was also associated with a lower risk of poor performance on the VST-283 
Complex task (complex processing speed; MEDAS Continuous: OR (95% CI) = 0.803 (0.660, 284 
0.977), P = 0.029; Pyramid: OR (95% CI) = 0.820 (0.675, 0.995), P = 0.045).   285 
 286 
**INSERT FIGURE 2 HERE** 287 
 288 
When participants were grouped by CVD risk (below and above the median QRISK2 score; 289 
Figure 2; Supplementary Table 5), no associations between MedDiet adherence and risk of 290 
poor cognitive performance in individuals with low CVD risk emerged.  However, in 291 
individuals at high CVD risk, MedDiet adherence as defined by the MEDAS Continuous score 292 
was associated with lower risk of poor HVLT performance (verbal episodic memory; OR (95% 293 
CI) = 0.756 (0.596, 0.958), P = 0.021).  Additionally, in high CVD risk individuals, moderate 294 
MedDiet adherence defined by the MEDAS Continuous score was associated with lower risk 295 
of poor VST-Complex performance (complex processing speed; OR (95% CI) = 0.728 (0.565, 296 
0.939), P = 0.015).  Both moderate and high MedDiet adherence defined by the Pyramid score 297 
were associated with lower risk of poor VST-Complex performance in individuals with high 298 
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CVD risk (Moderate: OR (95% CI) = 0.707 (0.551, 0.908), P = 0.007; High: OR (95% CI) = 299 
0.667 (0.551, 0.871), P = 0.003).   300 
 301 
**INSERT FIGURE 2 HERE** 302 
 303 
Sensitivity analyses 304 
To test the robustness of associations between MedDiet adherence and cognitive function/ risk 305 
of poor cognitive performance, we used dietary data from HC2 instead of HC1  306 
(Supplementary Table 6 and 7).  Higher MedDiet adherence defined by one or more of the 307 
MedDiet scores was associated with better performance and/or lower risk of poor cognitive 308 
performance across several different cognitive tests (P < 0.05; SF-EMSE, VST-Simple, and 309 
VST-Complex).  However, unexpectedly, performance was worse in the Letter Cancellation 310 
task (P < 0.05; attention) with high MedDiet adherence defined by the MEDAS and MEDAS 311 
Continuous scores at HC2, and the risk of poor performance on this test was greater with high 312 
MedDiet adherence defined by the MEDAS score (P < 0.05). 313 
  314 
In analyses where diet scores were derived after sequential removal of individual MedDiet 315 
components, the significant positive associations with cognition remained reasonably stable 316 
(Supplementary Table 8 and 9), except for the removal of wine or fruit from the MEDAS 317 
score and wine from the MEDAS Continuous score, after which associations with SF-EMSE 318 
performance were no longer present (P > 0.05; global cognition).   When potential under- and 319 
over-reporters were excluded from the analysis according to the Goldberg cut offs, higher 320 
MedDiet adherence defined by the Pyramid score remained significantly associated with better 321 
SF-EMSE (global cognition), HVLT (verbal episodic memory), and VST-Simple (simple 322 
processing speed) performance, and was additionally significantly associated with higher VST-323 
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Complex (complex processing speed) performance.  Higher MedDiet adherence defined by the 324 
MEDAS continuous score was now significantly associated with higher HVLT performance, 325 
but associations with SF-EMSE performance were no longer significant.  Associations between 326 
the MEDAS and SF-EMSE performance were no longer significant (Supplementary Table 327 
10).   When we included an interaction term in the model for MedDiet * CVD risk category, 328 
we found the MedDiet was more effective in individuals with high versus low CVD risk at 329 
reducing the risk of poor cognitive performance (Supplementary Table 11), confirming the 330 
results from our stratified analyses. Finally, when we compared cohort characteristics between 331 
participants with and without complete cognitive testing data, we found that participants who 332 
completed all cognitive tests were overall significantly younger, more physically active, had a 333 
higher educational attainment, and lower systolic BP and QRISK2 score (all P< 0.05; 334 
Supplementary table 12).  335 
 336 
DISCUSSION 337 
Using data on 8009 middle and older aged participants from EPIC-Norfolk, we found that 338 
higher adherence to the MedDiet was associated with better cognitive function and lower risk 339 
of poor cognitive performance across several cognitive tests/domains.  In stratified analyses, 340 
higher MedDiet adherence was associated with a lower risk of poor cognitive performance only 341 
in individuals at higher CVD risk.   342 
 343 
MedDiet and cognitive function/ risk of poor cognitive performance 344 
This is the first, large-scale prospective study exploring associations between an a priori 345 
defined MedDiet and cognitive function/poor cognitive performance in a UK population. We 346 
found that higher MedDiet adherence defined by one or more MedDiet scores was associated 347 
with better global cognition, verbal episodic memory, and simple processing speed, together 348 
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with a lower risk of poor global cognition, verbal episodic memory, complex processing speed, 349 
and prospective memory.  To put this into perspective, compared with the effects of age, which 350 
is the strongest determinant of cognitive decline (41), a 3 point increase in Pyramid score is 351 
equivalent to ~ 5 fewer years of ageing on global cognitive function. These findings are 352 
consistent with a recent study conducted in Greece by Anastasiou et al. (42), who reported that 353 
higher adherence to the Mediterranean lifestyle (encompassing the MedDiet plus physical 354 
activity, sleep, and daily activities) reduced risk of low global cognitive function equivalent to 355 
2.7 fewer years of ageing.  Delaying the onset of dementia by two- or five-years would reduce 356 
UK dementia prevalence by 19% and 33% by 2050, and result in much lower prevalence of 357 
severe dementia (43).  358 
 359 
In a previous, cross-sectional investigation conducted in 882 participants in the Lothian Birth 360 
Cohort 1936 study (19), higher adherence to a “Mediterranean-style” diet was associated with 361 
significantly better verbal ability in maximally adjusted models.  Other studies, conducted in 362 
non-Mediterranean countries, have shown inconsistent associations, with some investigations 363 
reporting positive associations (13–15) and others documenting no significant associations 364 
between MedDiet adherence and cognitive function (16–18).  Potential reasons for these 365 
conflicting findings could include differences in MedDiet capture, cognitive tests employed 366 
(e.g. varying sensitivity, assessment of different domains), study design (e.g. cross-sectional 367 
versus prospective) and follow up duration, and participant groups (e.g. divergent age profiles, 368 
healthy versus non-healthy cohorts).   369 
 370 
In stratified analyses, higher MedDiet adherence was associated with lower risk of poor 371 
cognitive performance only in participants with higher CVD risk. Mechanistically, this could 372 
be related to effects on both the systemic cardiovascular system and brain, including reduced 373 
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oxidative stress and inflammation (44), improved glucose and lipid metabolism (45), increased 374 
nitric oxide bioavailability, improved vascular function and brain perfusion (46,47). These 375 
findings have implications for the design of future RCTs, where individuals with higher CVD 376 
risk may represent a potentially responsive population group in which to study the cognitive 377 
benefits of the MedDiet.  This is the strategy that has been adopted for the MedEx-UK trial 378 
(https://clinicaltrials.gov/ct2/show/NCT03673722), which will explore the feasibility and 379 
acceptability of a MedDiet and physical activity intervention for dementia risk reduction and 380 
will recruit participants with a high QRISK2 score (used routinely in primary care in the UK 381 
to establish CVD risk) and subjective memory complaints.  Targeting individuals with and ‘at-382 
risk’ cardiovascular profile to improve MedDiet adherence may have a “double benefit”, not 383 
only by reducing CVD risk (as established in studies such as PREDIMED (3)), but also by 384 
improving cognitive function.  385 
 386 
Strengths and limitations 387 
Study strengths include the large sample size and the comprehensive assessment of cognitive 388 
function using a range of previously validated tests which cover multiple different domains 389 
that are affected during the early stages of cognitive decline prior to dementia onset.  Moreover, 390 
we used a prospective design in which dietary measures were obtained approximately 13 years 391 
before the cognitive assessments were made thus reducing the risk of reverse causality.  A 392 
further strength of this study is that we used two previously published, robustly defined 393 
measures of exposure to the MedDiet. In addition, we created a novel derivative of the MEDAS 394 
score where we coded intake of foods continuously rather than on a binary basis, which was 395 
more sensitive at quantifying individual diet quality and showed stronger links with cognitive 396 
outcomes.  However, although dietary data were derived from a validated FFQ, this instrument 397 
may not provide sufficient detail about the consumption of some foods key to the MedDiet 398 
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pattern, such as the type and intake of olive oil, consumption of sofrito, and the type of nuts 399 
consumed (12).  Moreover, the scales we used to evaluate MedDiet adherence do not account 400 
for intake of supplements, which may contain several nutrients key to this dietary pattern (e.g. 401 
omega-3, 50% of which is obtained from supplements in the UK (48)).  Furthermore, for our 402 
primary analysis, dietary intake was assessed between 1993-1997, whilst cognitive function 403 
was assessed 13 to 18 years later, and it is possible that participants may have altered their diet 404 
during this follow up period.  Likewise, given cognitive function was only measured at one 405 
time point, we were unable to explore associations between MedDiet adherence and cognitive 406 
trajectories. In addition, despite adjusting for multiple covariates, our results may have been 407 
influenced by unmeasured variables.  For example, we did not measure participant IQ, which 408 
influences both cognitive performance and dietary choices (19), but we included education as 409 
a covariate which, typically, shows good correlation with IQ (49).  Finally, it is possible that 410 
there is a degree of selection bias in this study, which may limit the generalisability of our 411 
findings to the wider population. Indeed, participants with poorer cognition may have decided 412 
not to/ were unable to take part in data collection at HC3.  Alternatively, these individuals may 413 
have only completed a sub-set of tests at this phase.  In this regard, it is noteworthy that 414 
participants with incomplete cognitive data showed generally poorer health than those who 415 
completed all tests. It is difficult to speculate how this may have influenced our results, and 416 
future research is warranted to explore the impact of the MedDiet on cognition in different 417 
cohorts.   418 
 419 
Conclusions and implications 420 
This study provides evidence that higher MedDiet adherence is associated with better cognitive 421 
function and lower risk of poor cognitive performance in a UK population.  In addition, we 422 
demonstrated that the MedDiet is particularly associated with lower risk of poor cognitive 423 
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performance in individuals with higher CVD risk.  These results have implications for the 424 
development of dietary recommendations to facilitate healthy cognitive ageing. In addition, the 425 
findings suggests that individuals with higher CVD risk are a key population group for future 426 
RCTs testing lifestyle modifications to improve cognition during ageing.    427 
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Table 1 Participant characteristics at baseline (HC1) of the EPIC-Norfolk study according to Mediterranean diet adherence score  
Characteristic Mediterranean diet score 
Overall  MEDAS1 MEDAS Continuous Pyramid 
 Low =  
0 - 2 
n=2400 
Medium =  
3 - 4 
n=4198 
High = 
5 - 10 
n=1411 
P Low =  
1.31 - 4.97 
n=2670 
Medium = 
4.98 - 6.04 
n=2670 
High =  
6.05 - 10.87 
n=2669 
P Low = 
3.47 - 7.53 
n=2687 
Medium = 
7.54 - 8.66 
n=2673 
High = 
8.67-12.93 
n=2649 
P 
Age, Years 
 
 
55.0 (49.4, 
61.7) 
54.5 (49.1, 
61.6) 
55.3 (49.5, 
61.9) 
54.7 (49.5, 
61.2) 
0.131 55.5 (49.5,  
62.4) 
55.0 (49.3, 
61.6) 
54.5 (49.2 – 
61.0) 
0.002 54.9 (49.4, 
61.7) 
55.4 (49.5, 
61.8) 
54.9 (49.3, 
61.5) 
0.439 
Sex, % males 
 
44 51 44 34 <0.001 50 45 39 <0.001 54 44 36 <0.001 
BMI, kg/m2 
(n=7989) 
 
25.4 (23.3, 
27.7) 
25.5 (23.4, 
28.0) 
25.4 (23.4, 
27.7) 
24.9 (23.0, 
27.2) 
<0.001 25.6 (23.5, 
27.9) 
25.5 (23.5, 
27.8) 
25.0 (23.0 – 
27.4) 
<0.001 25.6 (23.6, 
28.0) 
25.4 (23.4, 
27.8) 
25.0 (23.0, 
27.4) 
<0.001 
Smoking status, % 
(n=7983) 
    <0.001    <0.001    <0.001 
Current 9 11 8 6  11 8 7  12 8 6  
Former 39 37 40 40  37 39 41  39 39 39  
Never 
 
52 51 53 54  52 54 52  49 53 55  
Physical activity level, %     0.001    <0.001    0.007 
Inactive 22 24 22 17  24 23 18  24 23 18  
Moderately inactive 30 29 30 32  29 30 31  28 31 32  
Moderately active 26 26 25 27  27 24 26  26 24 27  
Active 
 
23 21 23 25  21 23 25  22 23 23  
Education status 
(n=8012) 
    <0.001    <0.001    <0.001 
No education 26 30 26 19  33 26 20  34 26 18  
O-levels 12 12 12 11  12 13 11  12 12 12  
A-levels 44 44 44 46  43 44 46  43 46 44  
Degree 18 
 
14 18 24  13 17 23  11 17 25  
Systolic BP, mmHg 
(n=7993) 
 
130 (120, 
142) 
130 (121, 
142) 
131 (120, 
143) 
129 (119, 
141) 
0.046 131 (121, 
142) 
130 (120, 
143) 
129 (119, 
141) 
<0.001 132 (121, 
142) 
131 (120, 
142) 
129 (119, 
142) 
0.001 
Diastolic BP, mmHg 
(n=7993) 
 
81 (74, 88) 81 (74, 88) 81 (74, 88) 80 (73, 87) 0.010 81 (74, 88) 81 (74, 89) 80 (73, 87) 0.001 81 (74, 88) 81 (74, 88) 80 (73, 87) 0.001 
HDL cholesterol, mM 
(n=7419) 
 
1.4 (1.1, 
1.7) 
1.3 (1.1, 
1.6) 
1.4 (1.1, 
1.7) 
1.5 (1.2, 
1.8) 
<0.001 1.3 (1.1, 
1.6) 
1.4 (1.1, 
1.7) 
1.5 (1.2, 
1.8) 
<0.001 1.3 (1.1, 
1.6) 
1.4 (1.1, 
1.7) 
1.4 (1.2, 
1.8) 
<0.001 
LDL cholesterol, mM 
(n=7419) 
 
3.8 (3.1, 
4.5) 
3.8 (3.2, 
4.5) 
3.8 (3.1, 
4.5) 
3.7 (3.1, 
4.4) 
0.123 3.8 (3.2, 
4.5) 
3.8 (3.2, 
4.5) 
3.7 (3.1, 
4.4) 
0.002 3.9 (3.2, 
4.5) 
3.8 (3.1, 
4.5) 
3.7 (3.1, 
4.4) 
0.001 
Total triglycerides, mM 
(n=7592) 
1.4 (1.0, 
2.1) 
1.5 (1.0, 
2.2) 
1.4 (1.0, 
2.0) 
1.3 (0.9, 
1.9) 
<0.001 1.5 (1.0, 
2.2) 
1.5 (1.0, 
2.1) 
1.3 (0.9, 
1.9) 
<0.001 1.5 (1.0, 
2.2) 
1.4 (1.0, 
2.0) 
(1.4 (0.9, 
1.9) 
<0.001 
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Participant characteristics were compared between low, medium and high Mediterranean diet adherence groups for each score using the Kruskal-Wallis test for ordered and non-normally distributed continuous 
variables and the chi squared test for nominal variables.  Data are presented as median (IQR) for non-normally distributed continuous data and % for nominal/ categorical data. Where measurements were not obtained 
in the full set of 8009 participants, the exact number of participants for the variable is stated in brackets under the variable name.  1For the MEDAS score, it was not possible to divide participants into approximately 
equal sized groups, given a large number of participants achieved the same score.  Therefore, participants were split into three groups where all individuals with the same score were categorised together.   
 
 
 
QRISK2 score 
(n=7953) 
6.8 (3.0, 
14.0) 
7.3 (3.3, 
14.8) 
6.8 (3.1, 
14.1) 
5.8 (2.6, 
12.6) 
<0.001 7.6 (3.5, 
15.5) 
6.8 (3.0, 
13.9) 
5.8 (2.6, 
12.7) 
<0.001 7.7 (3.5, 
15.4) 
6.7 (3.0, 
13.8) 
6.0 (2.7, 
12.6) 
<0.001 
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Table 2 Mediterranean diet adherence and cognitive function in the EPIC-Norfolk study 
Outcome Cognitive 
domain 
Model MEDAS  MEDAS 
Continuous 
 Pyramid  
β + SE P β + SE P β + SE P 
SF-EMSE Global 
cognition 
1 -0.010 ± 0.002 <0.001 -0.013 ± 0.002 <0.001 -0.021 ± 0.002 <0.001 
2 -0.010 ± 0.002 <0.001 -0.013 ± 0.002 <0.001 -0.021 ± 0.002 <0.001 
3 -0.004 ± 0.002 0.019 -0.005 ± 0.002 0.008 -0.012 ± 0.002 <0.001 
4 -0.004 ± 0.002 
 
0.018 -0.005 ± 0.002 0.008 -0.012 ± 0.002 <0.001 
HVLT Retrospective 
memory 
(verbal 
episodic 
memory) 
 
1 -0.008 ± 0.002 <0.001 -0.010 ± 0.002 <0.001 -0.016 ± 0.002 <0.001 
2 -0.008 ± 0.002 <0.001 -0.010 ± 0.002 <0.001 -0.016 ± 0.002 <0.001 
3 -0.003 ± 0.002 0.147 -0.004 ± 0.002 0.058 -0.009 ± 0.002 <0.001 
4 -0.003 ± 0.002 
 
0.139 -0.004 ± 0.002 0.054 -0.009 ± 0.002 <0.001 
CANTAB-PAL Retrospective 
memory 
(non-verbal 
episodic 
memory) 
 
1 0.061 ± 0.036 0.096 0.085 ± 0.039 0.029 0.134± 0.037 <0.001 
2 0.065 ± 0.036 0.077 0.083 ± 0.039 0.027 0.137 ± 0.038 <0.001 
3 0.002 ± 0.036 0.967 0.007 ± 0.039 0.859 0.041 ± 0.038 0.279 
4 0.002 ± 0.036 
 
0.952 0.008 ± 0.039 0.842 0.042 ± 0.038 0.266 
Letter 
Cancellation 
Attention 1 0.038 ± 0.049 0.442 0.091 ± 0.053 0.084 0.146 ± 0.050 0.004 
2 0.042 ± 0.049 0.390 0.093 ± 0.053 0.074 0.138 ± 0.051 0.007 
3 -0.013 ± 0.049 0.795 0.024 ± 0.053 0.652 0.055 ± 0.052 0.282 
4 -0.012 ± 0.049 
 
0.801 0.024 ± 0.053 0.647 0.056 ± 0.052 0.276 
VST-Simple  Simple 
processing 
speed 
1 -0.001 ± 0.001 0.082 -0.002 ± 0.001 0.004 -0.003 ± 0.001 <0.001 
2 -0.001 ± 0.001 0.071 -0.002 ± 0.001 0.003 -0.003 ± 0.001 <0.001 
3 0.000 ± 0.001 0.431 -0.001 ± 0.001 0.082 0.002 ± 0.001 0.014 
4 -0.001 ± 0.001 
 
0.423 -0.001 ± 0.001 0.079 -0.002 ± 0.001 0.013 
VST-Complex Complex 
processing 
speed 
1 0.000 ± 0.001 0.762 -0.001 ± 0.001 0.078 -0.002 ± 0.001 0.025 
2 0.000 ± 0.001 0.637 -0.001 ± 0.001 0.055 -0.002 ± 0.001 0.014 
3 0.000 ± 0.001 0.947 -0.001 ± 0.001 0.145 -0.001 ± 0.001 0.058 
4 0.000 ± 0.001 0.939 -0.001 ± 0.001 0.141 -0.001 ± 0.001 0.056 
SF-EMSE, Short Form Extended Mini Mental State Exam (n = 7917); HVLT, Hopkins Verbal Learning Test (n = 7589); CANTAB-PAL, 
Paired Associates Learning Test from the Cambridge Automated Neuropsychological Test Battery (n = 6970); Letter cancellation (n = 7847); 
VST-Simple, Visual Sensitivity Test, simple version (n = 6685); VST-Complex, Visual Sensitivity Test, complex version (n = 6685). 
Associations were explored via linear regression. Model 1 was adjusted for age, sex, BMI, waist circumference, marital status, and employment 
status. Model 2 was additionally adjusted for self-reported medical conditions (heart attack, stroke, arrhythmia, diabetes, depression, and other 
psychological illness), self-reported medication (BP lowering, lipid lowering, steroids, diabetes medication), HDL and LDL cholesterol, total 
triglycerides, smoking status, physical activity status, systolic and diastolic BP. Model 3 was additionally adjusted for education. Model 4 was 
additionally adjusted for APOE E4 genotype. Scores for the SF-EMSE and HVLT were negatively skewed, and therefore log and reverse 
score transformed variables were derived. Lower transformed scores on these tests reflect better cognitive performance (i.e. greater original 
scores).  VST-Simple and VST-complex scores were log transformed (log10), whilst untransformed variables were used for the CANTAB-
PAL and Letter Cancellation Task.  Results are presented as β-coefficients and standard errors (SE). 
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FIGURE LEGENDS 
Figure 1 Mediterranean diet adherence and risk of poor cognitive performance across the SF-
EMSE (A; n = 7917), HVLT (B; n = 7589), VST-Complex (C; n = 6685), and Prospective 
Memory (D; n = 7841) tasks in the EPIC-Norfolk study. Poor performance was defined as a 
score in the bottom 10 % of the population distribution for each test. Results are expressed as 
odds ratios plus 95 % confidence intervals for poor cognitive performance with medium and 
high compared with the lowest tertile of Mediterranean diet adherence (dashed line). 
Associations were explored via logistic regression. * represents a significantly lower risk of 
poor cognitive performance compared with the lowest tertile of Mediterranean diet adherence 
(P < 0.05).  
 
Figure 2 Mediterranean diet adherence and risk of poor cognitive performance in individuals 
with low (shaded area) and high CVD risk across the HVLT (A; high risk n = 3685, low risk n 
= 3847) and VST-Complex (B; high risk n = 3207, low risk n = 3424) tasks in the EPIC-Norfolk 
study.   Participants were stratified into low and high risk groups for analysis by the median 
QRISK2 score. Poor performance was defined as a score in the bottom 10 % of the population 
distribution for each test. Results are expressed as odds ratios plus 95 % confidence intervals 
for poor cognitive performance with medium and high compared with the lowest tertile of 
Mediterranean diet adherence (dashed line). Associations were explored via logistic regression. 
* represents a significantly lower risk of poor cognitive performance compared with the lowest 
tertile of Mediterranean diet adherence in the same CVD risk category (P < 0.05). 
 
